IMPORTANT HERB-DRUG INTERACTIONS
Abstract
Background. Herbal medicines have been popular for self-medication for a long time. Patients consider them to be safe because of their natural origin. Concurrent use of herbal medicines with other drugs can lead to interactions that are manifested as amplified or reduced pharmacological or toxic effect of any of the pair. It is worrying that patients use herbal medicines with prescribed or OTC drugs without informing the physician.
Conclusions. Many herbal medicines influence the action of numerous drugs. Medicinal plants most often involved in the interactions are St. John’s wort (Hypericum perforatum), garlic (Allium sativum), ginkgo (Ginkgo biloba), ginseng (Panax ginseng), kava (Piper methysticum), and grapefruit (Citrus paradisi). Dangerous interactions are more likely to occur in perioperative patients as they use many prescribed drugs at the same time. Also sensitive to interactions are transplant patients, patients on anticoagulants and HIV patients receiving antiretroviral therapy. Physicians should consider possible interactions with herbal medicines when prescribing drugs and before operations. Patients should be asked if they use any of the above listed herbs. Physicians should warn them about the dangers of simultaneous use of those herbs and prescribed or OTC drugs.
Downloads
References
Mahady GB, Parrot J, Lee C et al. Botanical dietary supplement use in periand postmenstrual women. Menopause 2003; 10: 65–72.
Kaye AD, Clarke RC, Sabar R, Vig S, Dhawan KP, Hofbauer R, Kaye AM. Herbal medicines: current trends in anesthesiology practice – a hospital survey. J Clin Anesth 2000; 12: 468–71.
Klemenc-Ketiš Z, Verovnik F. Uporaba zdravilnih rastlin med prebivalci Velenja. Zdrav Vestn 2004; 73: 59–62.
Kralj M. Ovrednotenje uporabe in odnosa uporabnikov do zdravilnih rastlin in njihovih pripravkov pri samozdravljenju. Diplomska naloga. Ljubljana: Univerza v Ljubljani, Fakulteta za farmacijo, 2001.
Blumenthal M. Herbs continue slide in mainstream market: sales down 14 percent. Herbal Gram 2003; 58: 71–1.
Scimone A, Scimone A. US sees the green in herbal supplements. Chemical Market Reporter (New York) 1998; 254: FR3–4.
Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 2001; 61: 2163–75.
Anonymous. EGb 761: ginkgo biloba extract, Ginkor. Drugs in R&D 2003; 4: 188–93.
Vaes LP, Chyka PA. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evidence. Ann Pharmacother 2000; 34: 1478–82.
Fugh-Berman A, Ernst E. Herb-drug interactions: Review and assessment of report reliability. Br J Clin Pharmacol 2001; 52: 587–95.
Shinozuka K, Umegaki K, Kubota Y et al. Feeding of Ginkgo biloba extract (GBE) enhances gene expression of hepatic cytochrome P-450 and attenuates the hypotensive effect of nicardipine in rats. Life Sci 2002; 70: 2783–92.
Valli G, Giardina EG. Benefits, adverse effects and drug interactions of herbal therapies with cardiovascular effects. J Am Coll Cardiol 2002; 39: 1083–95.
Fugh-Berman A. Herb-drug interactions. Lancet 2000; 355: 134–8.
EMEA, The European Agency for the Evaluation of Medicinal Products, Evaluation of Medicines for Human Use. EMEA public statement on the risk of drug interactions with Hypericum perforatum (St. John’s wort) and antiretroviral medicinal products. London: EMEA/6321/00, 28 February, 2000.
Mlinarič A. Interakcije hipopilemikov z učinkovinami naravnega izvora. Farm Vestn 2003; 54: 694–4.
Thompson Coon JS, Ernst E. Herbs for serum cholesterol reduction: A systematic review. J Fam Pract 2003; 52: 468–78.
Kane GC, Lipsky JJ. Drug-grapefruit juice interactions. Mayo Clin Proc 2000; 75: 933–42.
Gruenwald J, Brender T, Jaenicke C. PDR for herbal medicines, 2nd ed. Montvale, NJ: Medical Economics Company, 2000: 271–5, 469–74, 843–6.
Štrukelj B. Gastrointestinalni sistem. In: Doljak B, Štrukelj B, Mlinarič A. Zdravila naravnega izbora in sodobna fitoterapija. Ljubljana: Fakulteta za farmacijo, 2003: 120–34.
Elvin-Lewis M. Should we be concerned about herbal remedies. J Ethnopharmacol 2001; 75: 141–64.
Mlinarič A, Kreft S, Krbavčič A, Umek A. Efedrin v prehranskih dopolnilih. Farm Vestn 1998; 49: 436–44.
Wooltorton E, Sibbald B. Ephedra/ephedrine: cardiovascular and CNS effects. CMAJ 2002; 166: 633–3.
Cupp MJ. Herbal remedies: adverse effects and drug interactions. Am Fam Physician 1999; 59: 1239–44.
Food and Drug Administration. Final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk. Federal Register: February 11, 2004 (Vol. 69, Number 28): 6787–854, dostopno na http://fr.cos.com/cgi-bin/getRec?id = 20040211a160
Kemper KJ. Ephedra (Ephedra sinica). The Longwood herbal task force, 2000. http://www.mcp.edu/herbal/ephedra/ephedra.pdf, dostopno 10. marca 2003.
Tankanow R, Tamer HR, Streetman DS et al. Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha). J Clin Pharmacol 2003; 43: 637–42.
Bano G, Raina RK, Zutshi U et al. Effect of piperine on bioavailability and pharmacokinetics of propranolol and theophylline in healthy volunteers. Eur J Clin Pharmacol 1991; 41: 615–7.
Bhardwaj RK, Glaeser H, Becquemont L, Klotz U, Gupta SK, Fromm MF. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002; 302: 645–50.
Khajuria A, Thusu N, Zutshi U. Piperine modulates permeability characteristics of intestine by inducing alterations in membrane dynamics: influence on brush border membrane fluidity, ultrastructure and enzyme kinetics. Phytomedicine 2002; 9: 224–31.
World Health Organization. Semen Plantaginis. In: WHO monographs on selected medicinal plants, Volume 1. Geneva: WHO, 1999: 202–12.
Fahey JW, Talalay P. Antioxidant functions of sulforaphane: a potent inducer of phase II detoxication enzymes. Food Chem Toxicol 1999; 37: 973–9.
Sorensen JM. Herb-drug, food-drug, nutrient-drug, and drug-drug interactions: mechanisms involved and their medical implications. J Altern Complement Med 2002; 8: 293–308.
Zou L, Harkey MR, Henderson GL. Effects of herbal components on cDNAexpressed cytochrome P450 enzyme catalytic activity. Life Sci 2002; 71: 1579–89.
Bilia AR, Gallori S, Vincieri FF. Kava-kava and anxiety: growing knowledge about the efficacy and safety. Life Sci 2002; 70: 2581–97.
Centers for Disease Control and Prevention. Hepatic toxicity possibly associated with kava-containing products. JAMA 2003; 289: 36–7.
Bundesinstitut für Arzneimittel und Medizinprodukte. Bundesinstitut für Arzneimittel und Medizinprodukte widerruft Zulassungen Kava-Kava- und Kavain-haltiger Arzneimittel. BfArM Pressemitteilung 10/02. 17. Juni 2002, dostopno na http://www.bfarm.de/de/Presse/mitteil_2002/index.php?more=0210.php
Stevinson C, Huntley A, Ernst E. A systematic review of the safety of kava extract in the treatment of anxiety. Drug Saf 2002; 25: 251–61.
Ernst E. The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John’s Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Ann Intern Med 2002; 136: 42–53.
Ang-Lee MK, Moss J, Chun-Su Y. Herbal medicines and perioperative care. JAMA 2001; 286: 208–16.
Lyons TR. Herbal medicines and possible anesthesia interactions. AANA J 2002; 70: 47–51.
Rosen MI, Kosten TR, Kreek MJ. The effects of naltrexone maintenance on the response to yohimbine in healthy volunteers. Biol Psychiatry 1999; 45: 1636–45.
Velpandian T, Jasuja R, Bhardwaj RK et al. Piperine in food: interference in the pharmacokinetics of phenytoin. Eur J Drug Metab Pharmacokinet 2001; 26: 241–7.
Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. St. John’s wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002; 54: 349–56.
Moschella C, Jaber BL. Interaction between cyclosporine and Hypericum perforatum (St. John’s wort) after organ transplantation. Am J Kidney Dis 2001; 38: 1105–7.
Hebert MF, Park JM, Chen YL, Akhtar S, Larson AM. Effects of St. John’s wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 2004; 44: 89–94.
Piscitelli SC, Burstein AH, Welden N, Gallicano KD, Falloon J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002; 34: 234–8.
Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St. John’s wort. Lancet 2000; 335: 547–8. Erratum in: Lancet 2001; 357: 1210.
Abebe W. An overview of herbal supplement utilization with particular emphasis on possible interactions with dental drugs and oral manifestations. J Dent Hyg 2003; 77: 37–46.
Hiwale AR, Dhuley JN, Naik SR. Effect of co-administration of piperine on pharmacokinetics of beta-lactam antibiotics in rats. Indian J Exp Biol 2002; 40: 277–81.
Murphy PA. St. John’s wort and oral contraceptives: reasons for concern? J Midwifery Womens Health 2002; 47: 447–50.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
